Neurocognitive performance after PCSK9 inhibitor therapy: Current state of the evidence

J Neurosci Res. 2018 May;96(5):762-764. doi: 10.1002/jnr.24199. Epub 2017 Nov 20.

Authors

Cosimo Andrea Stamerra¹, Paolo Di Giosia¹, Paolo Giorgini¹, Martina De Feo¹, Davide Grassi¹, Claudio Ferri¹, Amirhossein Sahebkar^{2

3}

Affiliations

¹ Department of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
² Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
³ School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.

PMID: 29152786
DOI: 10.1002/jnr.24199

No abstract available

Keywords: PCSK9 inhibitors; atherosclerosis; lipids; neurocognitive events; statins.

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized / administration & dosage
Antibodies, Monoclonal, Humanized / adverse effects
Anticholesteremic Agents / administration & dosage
Anticholesteremic Agents / adverse effects*
Cognition Disorders / chemically induced*
Cognition Disorders / metabolism
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects
Hypercholesterolemia / drug therapy*
Hypercholesterolemia / metabolism
Hypercholesterolemia / psychology
PCSK9 Inhibitors*
Randomized Controlled Trials as Topic

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
PCSK9 Inhibitors
PCSK9 protein, human
evolocumab